TORONTO, July 28, 2016 /CNW/ - Ferring Canada, a subsidiary of Ferring Pharmaceuticals announced today the availability inCanada of CORTIMENT® MMX (budesonide delayed and extended release tablets) treatment for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), one of the two most common types of inflammatory bowel disease (IBD). Canadahas among the highest reported rates of IBD in the world. Ulcerative colitis is a condition that can be very debilitating and significantly compromise quality of life. Approximately 104,000 Canadians are living with UC.
Newsroom
Thursday, 28 July 2016